Biophytis announces its management will participate and meet with investors at the following upcoming events and conferences: H. C. Wainwright 23rd Annual Global Investment ConferenceSeptember 13 to 15 – Virtual Amsterdam MidCap EventSeptember 20 to 21 – Virtual Investor Access EventSeptember 27 to 28 – Paris HealthTech Innovation DaysOctober 4 to 5 – Paris European…
Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19
Biophytis announces today that it has performed the obligations imposed on it by (i) the judgment of the Commercial Court of Paris (Tribunal de commerce de Paris) of March 16, 2021 and (ii) the judgment of July 16, 2021 of the Enforcement Judge of the Judicial Court of Paris (Juge de l’exécution du Tribunal Judiciaire…
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.